BI-882370

N/A

Report date: 2024/03/29 14:10:35
NME

Base Information

Drug NameBI-882370
Drug Alias NameXP-102BI-882370XP-102SCXP102SC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitors
TargetsSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXynomic Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A